Should GLP-1 agonists like Ozempic and Wegovy be banned for professional athletes?

Partially SupportedGLP-1 agonists have profound efficacy and unquestionable short-term safety for body weight regulation.

Partially SupportedObesity with a strong genetic predisposition could be considered a disability, raising fairness issues regarding drug access and potential discrimination.

Partially SupportedDrugs that increase red blood cell count, accelerate muscle repair, or reduce body weight are prohibited in sports.

Partially SupportedDrugs that improve athletic performance, such as testosterone, growth hormone, or EPO, are banned by WADA and USADA.

Partially Supported